

Asthma Indicators for LHIN 2: South West

Indicator	Asthma Indicators for LHIN 2: South West																						
	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017*	2018*
1. PFT used for diagnosis (% of incident asthma) [†]	36.28	36.36	35.29	38.14	37.03	40.07	41.07	42.21	41.72	45.15	45.10	45.61	47.37	47.11	48.49	48.83	47.09	48.38	50.92	52.61	54.32	55.92	55.51
2. PFT used for monitoring (% of prevalent asthma) [†]	9.53	8.84	8.46	7.93	7.47	7.13	7.24	6.54	6.05	6.02	5.84	5.98	5.84	5.87	5.67	5.54	5.33	4.89	5.00	5.37	5.36	5.49	5.48
3. ≥1 ICS prescription (% of prevalent asthma) [‡]	58.75	57.41	56.59	54.82	54.95	54.06	53.46	51.69	51.65	52.13	51.70	51.05	50.58	50.04	50.00	50.99	50.18	50.50	49.43	49.78	48.80	46.94	44.37
4. ≥1 β2-agonist prescription (% of prevalent asthma) [‡]	63.75	62.03	60.58	58.49	57.52	56.07	53.94	51.22	49.18	47.33	45.97	45.49	43.04	41.55	41.52	41.63	39.50	39.42	35.43	25.73	25.46	23.35	23.94
5. ≥1 asthma ED visit (% of prevalent asthma)	6.72	5.50	4.61	4.22	4.24	3.82	3.66	3.17	3.37	3.00	3.14	2.97	2.53	2.46	2.22	1.94	1.73	1.68	1.41	1.51	1.37	1.38	1.45
6. ≥1 asthma physician office visit (% of prevalent asthma)	36.31	31.86	29.06	27.12	25.01	23.90	21.53	19.86	18.91	17.84	16.67	16.33	14.90	14.28	13.98	13.01	12.32	11.53	10.77	10.91	10.63	10.49	10.17
7. β2-agonist use (% of prevalent asthma) [‡]																							
0	36.25	37.97	39.42	41.51	42.48	43.93	46.06	48.78	50.82	52.67	54.03	54.51	56.96	58.45	58.48	58.37	60.50	60.58	64.57	74.27	74.54	76.65	76.06
1-2	16.82	18.21	18.18	18.23	18.14	19.22	18.74	18.60	18.68	19.00	18.92	19.39	19.20	18.78	18.94	19.16	18.05	18.95	16.78	12.27	12.33	11.46	11.61
≥3	46.94	43.82	42.40	40.25	39.38	36.85	35.20	32.62	30.50	28.33	27.05	26.10	23.85	22.78	22.58	22.47	21.46	20.47	18.65	13.46	13.13	11.89	12.33

*Reporting period is from April 1996 to March 2019. Data for 2017 and 2018 may be incomplete due to the 2-year algorithm to identify asthma, and numbers are subject to change.

PFT = pulmonary function test; ICS = inhaled corticosteroid; ED = emergency department; ODB = Ontario Drug Benefit; OHIP = Ontario Health Insurance Plan; LHIN = Local Health Integration Network; HSU = health services use

[†]PFT data refers to individuals aged 7-99 years in the asthma prevalent population.

[‡]Drug use data refers to individuals aged 66-99 years with complete year ODB coverage in the asthma prevalent population.

Technical notes:

^aOHIP data was up to December 2019 when the tables were created.

^bFor asthma incidence from July 2017 to March 2019, PFT data for 2.5-year post asthma incidence are not complete as latest data were available up to December 2019 when the tables were created.

^cIndividuals with missing LHIN, rurality, or without OHIP coverage were excluded.

^dAsthma incidence of the year were excluded from this table, except for indicator 1.

^eIndex date is defined as the first service date of asthma HSU, or any HSU if there was no asthma HSU, or April 1 if there was no HSU during the year.

Asthma indicators - detailed description:

1. Percent of asthma incidence aged 7 years and above with a PFT in one year prior to or 2.5 years after incidence date^{a-c}
2. Percent of asthma prevalence aged 7 years and above with a PFT in one year prior to the index date^{a,c-e}
3. Percent of asthma prevalence 66 years and above with at least one prescription of ICS in one year prior to the index date^{c-e}
4. Percent of asthma prevalence aged 66 years and above with at least one prescription of β2-agonist in one year prior to the index date^{c-e}
5. Percent of asthma prevalence with at least one ED visit in one year prior to the index date^{c-e}
6. Percent of asthma prevalence with at least one physician office visit in one year prior to the index date^{c-e}
7. Distribution of the three categories of β2-agonist use for asthma prevalence aged 66 years and above^{c,d}

Source: This table uses statistics reported by the Ontario Asthma Surveillance Information System (OASIS) and data provided by ICES, Ontario.